Stella Diagnostics, Inc. (STELLA DIAGNOSTICS INC.) aksje

Stella Diagnostics, Inc., a research diagnostics company, engages in developing molecular diagnostics tools and new drug targets for esophageal diseases. It uses targeted mass spectrometry to determine the level of disease progression in tissue of the lower esophagus. The company's technology informs gastroenterologists, surgical oncologists, and pathologists, which patients are high risk for disease progression into precancer or cancer. The company was formerly known as JMP Properties, Inc. and changed its name to Stella Diagnostics, Inc. in April 2021. Stella Diagnostics, Inc. is headquartered in Salt Lake City, Utah.